Ovoca Bio Plc
OVXA | IR
Overview
Corporate Details
- ISIN(s):
- IE0006649010 (+1 more)
- LEI:
- 213800ST2AK5XQ1O5207
- Country:
- Ireland
- Address:
- 17 PEMBROKE STREET UPPER, D02 AT22 DUBLIN
- Website:
- https://ovocabio.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Ovoca Bio is a clinical-stage biopharmaceutical company focused on women’s health. In 2018 the Company acquired control of IVIX, a biotechnology company developing Orenetide (BP-101), a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). Since the initial acquisition, Ovoca Bio has supported the continued clinical development and commercial planning of Orenetide, which has been submitted for marketing authorisation in Russia and has commenced a Phase II study in a western population with HSDD. In March 2020, Orenetide became a fully owned program of Ovoca Bio. Founded and incorporated in Ireland, the business currently operates in Ireland, the UK and Russia.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-05 08:00 |
Delisting Announcement
Delisting from Euronext Growth Exchange
|
English | 9.0 KB | |
| 2025-03-03 15:00 |
Board/Management Change
Management Changes
|
English | 8.0 KB | |
| 2024-12-18 19:00 |
Declaration of Voting Results & Voting Rights Announcements
Result of AGM
|
English | 7.1 KB | |
| 2024-11-18 08:00 |
General Meeting Notice
Notice of AGM
|
English | 7.0 KB | |
| 2024-10-11 18:30 |
Major Shareholding Notification
Holding(s) in Company
|
English | 6.8 KB | |
| 2024-10-09 18:45 |
Transaction in Own Shares
Sale of Treasury Shares
|
English | 6.0 KB | |
| 2024-09-25 08:00 |
Earnings Release
Half-year Report
|
English | 7.6 KB | |
| 2024-09-02 15:30 |
Regulatory News Service
Consultancy Agreement
|
English | 8.7 KB | |
| 2024-07-15 08:00 |
Directors' Dealings
Director/PDMR Shareholding
|
English | 27.4 KB | |
| 2024-07-15 08:00 |
Board/Management Change
Directorate Change
|
English | 8.8 KB | |
| 2024-06-28 08:00 |
Report Publication Announcement
Annual Financial Report
|
English | 14.5 KB | |
| 2024-06-20 00:00 |
Annual Report
|
English | 1.2 MB | |
| 2024-01-23 08:00 |
Major Shareholding Notification
Holding(s) in Company
|
English | 7.9 KB | |
| 2023-12-01 13:00 |
Declaration of Voting Results & Voting Rights Announcements
Result of AGM
|
English | 7.8 KB | |
| 2023-11-07 10:15 |
General Meeting Notice
Notice of AGM
|
English | 8.3 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Stayble Therapeutics AB | Sweden | STABL | |
|
Stem Cells Spin Spolka Akcyjna | Poland | SCS | |
|
Strategic Partners A/S | Denmark | STRAP | |
|
STRIX GROUP PLC | Isle of Man | KETL | |
|
Swedish Orphan Biovitrum | Sweden | SOBI | |
|
SynAct Pharma | Sweden | SYNACT | |
|
SYNAIRGEN PLC | United Kingdom | SNG | |
|
Synthaverse S.A. | Poland | BML | |
|
Taurus Energy AB | Sweden | TAUR B | |
| Themis GREN Ltd. | Israel | TMIS |